Richard R. Furman, MD, Richard A. Stratton Assistant Professor in Hematology and Oncology, Weill Cornell Medical College, gives an overview of the efficacy and safety of idelalisib and rituximab for previously treated CLL.
Clinical Pearls: Results
Richard R. Furman, MD, Richard A. Stratton Assistant Professor in Hematology and Oncology, Weill Cornell Medical College, gives an overview of the efficacy and safety of idelalisib and rituximab for previously treated chronic lymphocytic leukemia (CLL).
Idelalisib + rituximab demonstrated an improvement in progression-free survival (PFS) compared with placebo + rituximab [HR = 0.15]
Median PFS was not reached in idelalisib arm and was 5.5 months in placebo arm
Overall survival benefit was also identified in idelalisib arm
Clinical Pearls: Adverse Events
There was a decrease in the risk of infusion reaction in the idelalisib arm
6 patients in the idelalisib arm experienced transaminitis
In this analysis, patients treated with idelalisib did not see an increased risk of diarrhea
